Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
672results about "Epidermal growth factors" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
P-amidobenzylethers in drug delivery agents
InactiveUS20030130189A1Decrease in drug activityImprove stabilityTetrapeptide ingredientsTripeptide ingredientsEtherDiluent
Compounds of the formulas LAn-Z-X-WwD and BZ-X-WwD wherein: D is a drug moiety; L is a ligand; B is a blocking group; A is an optional acyl unit; Z is an amino acid or a peptide; X is an aminobenzyl ether self-immolative spacer group; W is an optional second self-immolative group; n is an integer of 0 or 1; and w is an integer of 0 or 1, and compositions of said compounds with pharmaceutically acceptable carrier, diluent and / or excipient, and methods of delivery the drug D via the compounds.
Owner:SEAGEN INC
Novel proteins with targeted binding
InactiveUS20050089932A1Stimulate and inhibit activityEasy screeningPeptide librariesPeptide/protein ingredientsMonomerComputational biology
Methods for identifying discrete monomer domains and immuno-domains with a desired property are provided. Methods for generating multimers from two or more selected discrete monomer domains are also provided, along with methods for identifying multimers possessing a desired property. Presentation systems are also provided which present the discrete monomer and / or immuno-domains, selected monomer and / or immuno-domains, multimers and / or selected multimers to allow their selection. Compositions, libraries and cells that express one or more library member, along with kits and integrated systems, are also included in the present invention.
Owner:AMGEN MOUNTAIN VIEW
c-Met kinase binding proteins
InactiveUS20060008844A1Stimulate and inhibit activityCompound screeningPeptide librariesKinase bindingC-Met
Owner:AMGEN MOUNTAIN VIEW
LDL receptor class A and EGF domain monomers and multimers
InactiveUS20050164301A1High affinityStimulate and inhibit activityPeptide librariesPeptide/protein ingredientsMonomerIntegrated systems
Specific monomer domains and multimers comprising the monomer domains are provided. Methods, compositions, libraries and cells that express one or more library member, along with kits and integrated systems, are also included in the present invention.
Owner:AMGEN MOUNTAIN VIEW
EGFR mutations
The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and / or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.
Owner:GENENTECH INC
Administration of growth factors for the treatment of CNS disorders
ActiveUS20070254842A1Prevents and delay onsetReduce severityHeavy metal active ingredientsSenses disorderDiseaseNervous system
A method and system that is directed to the local delivery of growth factors to the mammalian CNS to treat CNS disorders associated with neuronal death and / or dysfunction is described.
Owner:RGT UNIV OF CALIFORNIA
Megalin-based delivery of therapeutic compounds to the brain and other tissues
InactiveUS20050042227A1Easy to transportImprove propertiesBiocideNervous disorderBlood–brain barrierDrug delivery
Owner:HORIZON ORPHAN LLC
Non-aqueous single phase vehicles and formulations utilizing such vehicles
InactiveUS20050008661A1Increase stickinessReduce occlusionPowder deliveryPeptide/protein ingredientsEngineeringSolvent
The present invention includes materials and methods for providing vehicles useful for providing drug formulations that address the potential drawbacks of known nonaqueous formulations. In particular, the present invention includes nonaqueous vehicles that are formed using a combination of polymer and solvent that results in a vehicle that is miscible in water. The nonaqueous vehicles facilitate the formulation of drug formulations that are stable over time, even when stored at, or exposed to, elevated temperatures. Moreover, the miscible vehicles of the present invention allow the preparation of drug formulations that work to reduce the occurrence of partial or complete occlusions of the delivery conduits included in delivery devices used to administer the drug formulations.
Owner:DURECT CORP
Decellularized bone marrow extracellular matrix
ActiveUS20050013872A1Minimizes and avoids immune responsePeptide/protein ingredientsSkeletal disorderCell-Extracellular MatrixInsertion stent
The invention is directed to compositions comprising decellularized bone marrow extracellular matrix and uses thereof. Methods for repairing or regenerating defective, diseased, damaged or ischemic tissues or organs in a subject, preferably a human, using the decellularized bone marrow extracellular matrix of the invention are also provided. The invention is further directed to a medical device, preferably a stent or an artificial heart, and biocompatible materials, preferably a tissue regeneration scaffold, comprising decellularized bone marrow extracellular matrix for implantation into a subject.
Owner:BOSTON SCI SCIMED INC
Composition for long-acting peptide analogs
ActiveUS20090088387A1Increase perfusionImprove the level ofAntibacterial agentsPeptide/protein ingredientsHalf-lifeArginine
The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)x-Peptide, wherein A is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidodiacetic acid group, or 4) a moiety of formula (ZyHisw)p, wherein Z is any amino acid residue other than histidine, His is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if A has alkyl group with 6 to 36 carbon units x is greater than 0; and Cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or N-Arginine or N-lysine, wherein x is an integer between 0-6 and N may be any amino acid or none. The peptide analogs are complexed with polymeric carrier to provide enhanced half-life.
Owner:PHARMAIN CORP
Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
InactiveUS20060211639A1Reduce development riskGood effectBiocideHeavy metal active ingredientsTime scheduleCombination therapy
The invention involves administration of an immunostimulatory nucleic acid in combination with a cancer medicament for the treatment or prevention of cancer in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of drugs.
Owner:BRATZLER ROBERT +1
In-Situ Forming Porous Scaffold
A composition includes a viscous gel formed from a combination of a biodegradable polymer and a biocompatible solvent. The composition also includes a hydrophilic porogen, which may be incorporated in the viscous gel. The composition may form a porous scaffold in situ.
Owner:ALZA CORP
Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer
InactiveUS20090325877A1Reducing FASN activityInhibitory activityBiocidePeptide/protein ingredientsReceptor tyrosine kinase inhibitorFatty acid
A pharmaceutical combination product is disclosed that comprises a receptor tyrosine kinase inhibitor and a fatty acid synthase inhibitor, and to the use thereof in the manufacture of a medicament for use in the treatment or prophylaxis of cancer.
Owner:WYETH
Conjugation methods
ActiveUS20110003969A1Reduce potential steric hindrancePeptide/protein ingredientsMammal material medical ingredientsBiochemistryAntibody
This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues
Owner:IMMUNOGEN INC
Fusion proteins for blood-brain barrier delivery
ActiveUS20070081992A1Avoid significant immunogenic reactionAvoid significant reactionSenses disorderNervous disorderMediated transportBlood–brain barrier
The invention provides compositions, methods, and kits for increasing transport of agents across the blood brain barrier while allowing their activity once across the barrier to remain substantially intact. The agents are transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems. In some embodiments the agents are therapeutic, diagnostic, or research agents.
Owner:ARMAGEN TECH +1
Polymer-based sustained release device
ActiveUS20050271702A1Improve bioavailabilityMinimizes loss of activityPowder deliveryPeptide/protein ingredientsMedicineSugar
This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
Owner:ALKERMES PHARMA IRELAND LTD
Single-chain polypeptides
The invention relates to single-chain multimeric polypeptides comprising at least two units of a monomeric polypeptide linked via a peptide bond or a peptide linker, wherein the monomeric polypeptide is of a type that is biologically active in monomeric form, and to polypeptide conjugates having at least one non-polypeptide moiety covalently bound to an attachment group of the polypeptide. The polypeptide is preferably a G-CSF dimer bound to a polymer molecule, preferably to one or more polyethylene glycol molecules.
Owner:MAXYGEN HLDG +1
Methods and compositions for the repair and/or regeneration of damaged myocardium
InactiveUS20060239983A1Restoring functional integrityRestoring structuralBiocidePeptide/protein ingredientsMedicineCardiac muscle
Owner:NEW YORK MEDICAL COLLEGE
Multifactorial assay for cancer detection
InactiveUS20050069963A1Rapid and early detectionPeptide/protein ingredientsMicrobiological testing/measurementAnti her2Anti-MUC-1
Provided are methods for the rapid detection of ovarian cancer. The methods employ a multiplex immunoassay to detect levels of two or more of the markers EGF, G-CSF, IL-6, IL-8, CA-125, VEGF, MCP-1, anti-IL6, anti-IL8, anti CA-125, anti-c-myc, anti-p53, anti-CEA, anti-CA 15-3, anti-MUC-1, anti-survivin, anti-bHCG, anti-osteopontin, anti-PDGF, anti-Her2 / neu, anti-Akt1, anti-cytokeratin 19, cytokeratin 19, EGFR, CEA, kallikrein-8, M-CSF, FasL, ErbB2 and Her2 / neu in a sample of the patient's blood, where the presence of abnormal levels of two or more of the markers indicates the presence of ovarian cancer in the patient. An array also is provided to quantitate levels of these markers in a patient's blood. Also provided is a method of predicting onset of clinical ovarian cancer comprising determining the change in concentration over time of two or more of anti-Her2 / neu, anti-MUC-1, anti-c-myc, anti-p53, anti-CA-125, anti-CEA, anti-CA 72-4, anti-PDGFRα, IFNγ, IL-6, IL-10, TNFα, MIP-1α, MIP-1β, EGFR and Her2 / neu in a patient's blood.
Owner:UNIVERSITY OF PITTSBURGH
Multiribbon nanocellulose as a matrix for wound healing
InactiveUS20070053960A1Improve adaptabilityControl thicknessOrganic active ingredientsBiocideFiberWound healing
The present invention includes compositions and methods for the integration of a non-allergenic nanocellulose into a wound bed. The composition may be formed into a wide variety of implants, e.g., a suture, a sheet, a compress, a bandage, a band, a prosthesis, a fiber, a woven fiber, a bead, a strip, a clasp, a prosthesis, a catheter, a screw, a bone plate, a pin, a bandage or combinations thereof.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Pharmaceutical compositions for the stimulation of stem cells
InactiveUS20120301538A1Improve abilitiesOrganic active ingredientsPowder deliveryVeterinary pharmaceuticalsExcipient
The invention relates to a human or veterinary pharmaceutical composition (B) for the stimulation of stem cells, comprising at least two stem-cells-stimulating-agents and at least one pharmaceutically acceptable excipient.
Owner:CARDIO3 BIOSCI
Treatment for heart disease
InactiveUS20070059288A1Poor cell survival and engraftmentImprove heart functionBiocideVirusesDiseaseCORONARY ARTERY DISEASE/MYOCARDIAL INFARCTION
The present invention provides a system for treating heart disease using a combination of pro-angiogenesis therapy and cellular cardiomyoplasty. The system is particularly useful in treating patients with damaged myocardium due coronary artery disease, myocardial infarction, congestive heart failure, and ischemia. A pro-angiogenic factor (e.g., VEGF) or a means of delivering a pro-angiogenic factor (e.g., a genetically engineered adenovirus, adeno-asssociated virus, or cells) is administered to the heart in order to promote new blood vessel growth in an ischemic or damaged area of the patient's heart. Cells such as skeletal myoblasts or stem cells (e.g., mesenchymal stem cells) with the potential to divide, differentiate, and integrate themselves into the injured myocardium are then administered into the affected area of the heart. By inducing new blood vessels growth in the injured myocardium, the cells are better able to grow and become an integral part of the heart. The invention also provides kits for use in treating a patient using the inventive method. Such kits may contain cells, catheters, syringes, needles, cell culture materials, polynucleotides, media, buffers, etc.
Owner:MYTOGEN
Chimeric activators: quantitatively designed protein therapeutics and uses thereof
ActiveUS20110274658A1Reduced cell-activating propertyAvoid and reduce unwanted side effectObesity gene productsPeptide/protein ingredientsChimerin ProteinsApoptosis
Aspects of the invention provide methods for harnessing the potential of proteins that occur naturally (e.g., in humans) and that have serious but finite toxicity. Aspects of the invention relate to a quantitative systems-biological and structural approach to design a class Mof chimeric proteins that avoid the toxicity of protein drugs while retaining their desired activities. In particular, chimeric proteins containing a variant form of a natural protein fused to a targeting moiety may be administered to a subject to target a signal (e.g., induction of apoptosis) to particular cells without having a generalized toxic effect
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Multi-Active Microtargeted Anti-Aging Skin Cream Polymer Technology
InactiveUS20110305737A1Reduction in signWithout exacerbating acneCosmetic preparationsBiocideCosmetic creamLotion
A comprehensive, single agent cosmetic cream or lotion containing a high number of ingredients that target anti-aging in a defined manner. The cream or lotion contains a high number and variety of active substances that demonstrate excellent safety and efficacy in all of the various defined categories of skin aging, including but not limited to wrinkles, abnormal pigment or brown spots due to aging of the skin and an unexpectedly high efficacy in the reduction of redness and acne and rosacea blemishes.
Owner:MACRENE ACTIVES LLC
Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
InactiveUS20090304666A1Connective tissue peptidesPeptide/protein ingredientsAnticarcinogenCancer cell
A conjugate is disclosed herein, wherein the conjugate includes a ligand having the ability to specifically and stably bind to an external receptor or binding site on a tumor vasculature endothelial cell, wherein the external receptor or binding site is specific for tumor vasculature endothelial cells. The conjugate also includes an anticancer agent that is selectively toxic to cancer cells operatively attached to the ligand. The anticancer agent may be L-methioninase. Pharmaceutical compositions comprising the conjugate are also disclosed, as well as methods of treating a cancer tumor or cancer cells with a therapeutically effective amount of the conjugate.
Owner:THE BOARD OF RGT UNIV OF OKLAHOMA
Methods and pharmaceutical compositions for healing wounds
InactiveUS20060258562A1Effectively circumventedEnhance healing processPeptide/protein ingredientsGenetic material ingredientsSkin cellPkc isoforms
Methods and pharmaceutical compositions for inducing or accelerating a healing process of a damaged skin or skin wound, comprise modulating expression and / or activity of at least two PKC isoforms in skin cells colonizing the damaged skin or skin wound area.
Owner:BAR ILAN UNIV
Methods and compositions using Substance P to promote wound healing
InactiveUS20070154448A1Promote healingGrowth promoting activityOrganic active ingredientsBiocideSubstance KMammalian tissue
Healing of wounds in mammalian tissue may be enhanced by the application of certain neuropeptides, optionally in combination with known growth promoting hormones. Exemplary neuropeptides include tachykinins, such as Substance P, Substance K, and the like, as well as calcitonin gene-related peptides. The compositions may further include a polymeric delivery carrier and are utilized by applying to the site of the wound. Wounds may be vascular or avascular wounds. The compositions promote elaboration of cellular matrices and development of cellular attachment mechanisms in addition to stimulating cellular proliferation.
Owner:AUXANO BIOLOGICS
Augmentation of wound healing by elF-4E mRNA and EGF mRNA
InactiveUS7202226B2Promote wound healingImprove translationBiocideGenetic material ingredientsWound healingIncreased Protein Synthesis
There is provided a method of augmenting transient protein synthesis in a cell by delivering to the cell mRNA functionally related to protein production. Also provided is a method of augmenting transient protein synthesis in cells by increasing protein synthesis of growth factors from endogenous cellular mRNA and exogenous mRNA delivered to the cells. A treatment for transiently increasing protein production in cells, said treatment comprising mRNA functionally related to protein production is also provided. There is provided a method of augmenting wound healing by delivering mRNA functionally related to wound healing. Further provided is a therapeutic for transiently increasing protein synthesis in cells, said therapeutic comprising mRNA related to protein production.
Owner:DETROIT R&D
Polymer-based sustained release device
ActiveUS20070166352A1Improve bioavailabilityMinimizes loss of activityPowder deliveryOrganic active ingredientsMedicineSugar
This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
Owner:ALKERMES PHARMA IRELAND LTD +1
Wound healing polymeric networks
Owner:UNIVERSITY OF PITTSBURGH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com